QL615 / Qilu Pharma, QLSF Biotherapeutics - LARVOL DELTA

QL615, a tetraspecific T cell engager with highly restricted activity on MET and EGFR-positive tumors while providing co-stimulation via CD2 (AACR 2025) - "The TECAD's CD2-mediated co-stimulation enhanced in vitro killing of tumor cells ~30-fold over constructs with CD3 redirection alone and showed superior tumor growth control in vivo. QL615 is currently advancing toward a development decision and clinical evaluation."

Oncology • Solid Tumor • CD2 • EGFR